Deutsche Bank AG Takes Position in Metsera Inc. $MTSR

Key Points

• Deutsche Bank AG acquired 13,740 shares of Metsera Inc. (NASDAQ:MTSR) valued at approximately $374,000 during the first quarter.
• Several major hedge funds also invested in Metsera, with Alphabet Inc. leading with a new position worth $135 million, followed by Vanguard Group and others.
• Wall Street analysts have given Metsera a consensus "Buy" rating with a target price of $59.00, influenced by recent positive evaluations from Guggenheim, Bank of America, and Wells Fargo.

Deutsche Bank AG acquired a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,740 shares of the company's stock, valued at approximately $374,000.

Several other large investors also recently modified their holdings of the business. Alphabet Inc. bought a new stake in Metsera in the first quarter valued at approximately $135,059,000. Vanguard Group Inc. purchased a new position in shares of Metsera in the 1st quarter worth about $39,932,000. Massachusetts Financial Services Co. MA purchased a new stake in Metsera during the first quarter valued at about $13,111,000. Jennison Associates LLC purchased a new stake in shares of Metsera in the first quarter worth about $9,679,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Metsera during the first quarter valued at about $3,410,000.

Analysts Set New Price Targets

A number of analysts recently commented on MTSR shares. Wells Fargo & Company initiated coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target for the company. Wall Street Zen raised Metsera from a "sell" rating to a "hold" rating in a research report on Saturday. Guggenheim lifted their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Finally, Bank of America lifted their price objective on Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $59.00.

Metsera Trading Up 0.7%

Shares of NASDAQ:MTSR traded up $0.25 during mid-day trading on Friday, reaching $35.29. 1,057,997 shares of the company traded hands, compared to its average volume of 1,405,017. Metsera Inc. has a 52 week low of $12.30 and a 52 week high of $47.40. The company's 50 day moving average price is $33.99 and its 200-day moving average price is $28.48.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.